TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10068977

Group type: EXPERIMENTAL
Intervention: Lead levels measured in newborns and infants
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: ALA-d and Zn-PP levels measured in newborns and infants
Number of subjects: 55

Group type: COMPARATOR
Intervention: Comparison of urban vs rural subjects
Number of subjects: 55
Study: 8277768

Group type: COMPARATOR
Intervention: Cimetidine alone (800 mg twice a day)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Cimetidine with DMSO (500 mg, four times a day)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Cimetidine with allopurinol (50 mg, four times a day)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Cimetidine alone (800 mg at bedtime)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Cimetidine with DMSO (500 mg at bedtime)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Cimetidine with allopurinol (50 mg at bedtime)
Number of subjects: 363
Study: 2973595

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 174

Group type: COMPARATOR
Intervention: Cefotaxime-Amikacin combination
Number of subjects: 174
Study: 30016393

Group type: EXPERIMENTAL
Intervention: Active-suspension seat
Number of subjects: 40

Group type: COMPARATOR
Intervention: Industry-standard air-suspension seat
Number of subjects: 40
Study: 28851779

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVA) with verteporfin PDT (vPDT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravitreal aflibercept (IVA) with sham photodynamic therapy (sPDT)
Number of subjects: 50
Study: 26362691

Group type: EXPERIMENTAL
Intervention: Patient navigation and financial incentives
Number of subjects: 352

Group type: COMPARATOR
Intervention: Enhanced traditional care
Number of subjects: 352
Study: 24021498

Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 60
Study: 21527667

Group type: EXPERIMENTAL
Intervention: Blood-based lactate indexes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ventilation-based lactate indexes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood-based measures in hot condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acclimation effect on blood-based indexes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ventilation-based indexes after acclimation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood-based methods vs ventilation-based methods
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inflection point between steady-state lactate and rising lactate (INFL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ventilation-based predictions in hot condition after acclimation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood-based predictions in both environments after acclimation
Number of subjects: 20
Study: 18458204

Group type: EXPERIMENTAL
Intervention: Induction of catecholamine depletion (CD) by oral administration of alpha‐methylparatyrosine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham depletion using identical capsules containing hydrous lactose
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Induction of catecholamine depletion (CD)
Number of subjects: 28
Study: 17064580

Group type: EXPERIMENTAL
Intervention: Autotransfusion of washed red blood cells during CPB
Number of subjects: 32
Study: 15071276

Group type: EXPERIMENTAL
Intervention: Prophylactic implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 207

Group type: COMPARATOR
Intervention: Optimized medical therapy (ACE inhibitors, beta-blockers, aldosterone antagonists)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Prophylactic ICD therapy
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: MACAS study findings
Number of subjects: 207
Study: 10486880

Group type: EXPERIMENTAL
Intervention: rhIL-3
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8799518

Group type: EXPERIMENTAL
Intervention: Loading dose of 50 micrograms kg‐1 of diamorphine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Loading dose of 200 micrograms kg‐1 of diamorphine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: M3G formation clearance
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: M6G formation clearance
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: M3G metabolite clearance
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: M6G metabolite clearance
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: M3G: morphine steady-state plasma concentration ratio
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: M6G: morphine steady-state plasma concentration ratio
Number of subjects: 19
Study: 2262216

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 377932

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propranolol (both doses)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31899037

Group type: EXPERIMENTAL
Intervention: Healthy diet (HD; n=19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Typical Western diet (WD; n=21)
Number of subjects: 40
Study: 30770034

Group type: EXPERIMENTAL
Intervention: Calmer treatment, n = 5
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard care (facilitated tucking), n = 5
Number of subjects: 10
Study: 26615376

Group type: COMPARATOR
Intervention: 6 mg subcutaneous sumatriptan
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 15 mg/Kg intravenous valproate
Number of subjects: 37
Study: 24890527

Group type: EXPERIMENTAL
Intervention: Functional testing (exercise electrocardiogram, stress nuclear imaging, or stress echocardiogram)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Anatomical testing with ≥64‐slice multidetector coronary computed tomographic angiography
Number of subjects: 10000
Study: 22495786

Group type: EXPERIMENTAL
Intervention: Oral alcohol (1 g/kg) administration before ART
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Alcohol area under the curve in untreated HIV disease
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: C(max) in untreated HIV disease
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: C(min) in untreated HIV disease
Number of subjects: 15

Group type: COMPARATOR
Intervention: Post-ART alcohol administration
Number of subjects: 15
Study: 20623224

Group type: COMPARATOR
Intervention: Bilateral superficial cervical block with isotonic saline (group A; n = 56)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (group B; n = 52)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (group C; n = 54)
Number of subjects: 162
Study: 17983379

Group type: EXPERIMENTAL
Intervention: Pholcodine exposure
Number of subjects: 17

Group type: COMPARATOR
Intervention: Guaifenesin exposure
Number of subjects: 17
Study: 15860531

Group type: EXPERIMENTAL
Intervention: Hypoxia (P(ET,O2) from 100 to 50 mmHg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hypocapnia (voluntary hyperventilation with P(ET,O2) clamped at 100 and 50 mmHg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Normoxic hypocapnia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison with sea-level residents
Number of subjects: 18
Study: 12201614

Group type: EXPERIMENTAL
Intervention: General exercise
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: McKenzie treatment
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 9456999

Group type: EXPERIMENTAL
Intervention: Preterm IAI cases
Number of subjects: 610

Group type: COMPARATOR
Intervention: Term IAI cases
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Preterm IAI management
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Preterm IAI compared with preterm births without IAI
Number of subjects: 610
Study: 7621214

Group type: EXPERIMENTAL
Intervention: Topical 2% lidocaine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 54
Study: 3344936

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Cladosporium herbarum
Number of subjects: 22
Study: 31667835

Group type: EXPERIMENTAL
Intervention: Occiput posterior position
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Occiput transverse position
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Attempted assisted vaginal rotational delivery for occiput posterior babies
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Attempted assisted vaginal rotational delivery for occiput transverse babies
Number of subjects: 838
Study: 28780222

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Posterolateral Approach (PLA)
Number of subjects: 46
Study: 26188020

Group type: EXPERIMENTAL
Intervention: Oral antioxidant cocktail (AOC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 16
Study: 23107171

Group type: EXPERIMENTAL
Intervention: Multiphasic injection protocol (protocol II) with 89 mL Ioversol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard uniphasic injection protocol (protocol I) with 100 mL Ioversol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multiphasic injection protocol (protocol II)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard uniphasic injection protocol (protocol I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multiphasic injection technique
Number of subjects: 30
Study: 21969502

Group type: COMPARATOR
Intervention: Gemcitabine alone (1,000 mg/m(2)/wk for weeks 1 to 6, followed by 1 week rest, then for 3 of 4 weeks)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus radiotherapy (600 mg/m(2)/wk for weeks 1 to 5, then 4 weeks later 1,000 mg/m(2) for 3 of 4 weeks plus radiotherapy starting on day 1, 1.8 Gy/Fx for total of 50.4 Gy)
Number of subjects: 74
Study: 18335584

Group type: EXPERIMENTAL
Intervention: Inflamed tooth and implant sites
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Inflamed immediately loaded (IL) sites
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Gingival index
Number of subjects: 220
Study: 21266734

Group type: EXPERIMENTAL
Intervention: Hypoxia group (Hyp-Ex)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normoxia group (Norm-Ex)
Number of subjects: 14
Study: 15589194

Group type: EXPERIMENTAL
Intervention: Reward trials
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Penalty trials
Number of subjects: 11

Group type: COMPARATOR
Intervention: Neutral trials
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Reward conditioning
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Penalty conditioning
Number of subjects: 11
Study: 11575539

Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rapacuronium
Number of subjects: 6
Study: 9609978

Group type: EXPERIMENTAL
Intervention: Platelets from PSS patients
Number of subjects: 7

Group type: COMPARATOR
Intervention: Platelets from healthy controls (HC)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Platelets from both PSS patients and HC
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Platelets from PSS patients and HC
Number of subjects: 7
Study: 7821319

Group type: EXPERIMENTAL
Intervention: Oral amiodarone (single loading dose of 25.7 +/- 0.9 mg.kg-1 body weight)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravenous amiodarone (bolus infusion of 3-5 mg.kg-1 over 30 min, followed by continuous infusion of 10-15 mg.kg-1 for 24 h)
Number of subjects: 45
Study: 3209830

Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Triple antibiotic therapy (penicillin-gentamicin-metronidazole)
Number of subjects: 40
Study: 30225762

Group type: EXPERIMENTAL
Intervention: Religious psychotherapy emphasizing the importance of prayers (reading prayers 15 and 23 of the SahifehSajjadiyeh book at the beginning of treatment sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 30361399

Group type: EXPERIMENTAL
Intervention: Cooral intraoral cooling device
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ice cooling
Number of subjects: 180
Study: 26421385

Group type: EXPERIMENTAL
Intervention: MTX and ω‐3 fatty acids (1000 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: MTX and placebo
Number of subjects: 70
Study: 24503554

Group type: EXPERIMENTAL
Intervention: 4D echo‐planar J‐resolved spectroscopic imaging
Number of subjects: 20
Study: 22805060

Group type: EXPERIMENTAL
Intervention: Dopamine (amphetamine administration)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 2
Study: 20818716

Group type: EXPERIMENTAL
Intervention: Plasma filtration (twice weekly in Weeks 1, 2, 4, 7, and 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Plasma filtration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (methylprednisolone IV pulses only)
Number of subjects: 20
Study: 17666475

Group type: EXPERIMENTAL
Intervention: 2 ng/kg Escherichia coli endotoxin (LPS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15172848

Group type: EXPERIMENTAL
Intervention: Chorionic Villus Sampling (CVS)
Number of subjects: 3775

Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 3775
Study: 11437398

Group type: COMPARATOR
Intervention: Chlorambucil (CB): 10 mg daily for 6 weeks, followed by a 2‐week interval, with 3 subsequent 2‐week treatment periods at the same dose, separated by 2‐week intervals
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Chlorambucil (CB) given concurrently with interferon (IFN) at a dose of 3 x 10(6) units thrice weekly, subcutaneously, throughout the 18‐week treatment period
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Maintenance IFN at the same dose and schedule as initial treatment
Number of subjects: 204
Study: 9488619

Group type: EXPERIMENTAL
Intervention: Clodronate 1600 mg daily
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study: 7865162

Group type: EXPERIMENTAL
Intervention: Visual target selection paradigm with randomized series of target, nontarget and novel visual stimuli.
Number of subjects: 96
Study: 3046878

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 29957723

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 187
Study: 27569526

Group type: EXPERIMENTAL
Intervention: Machine learning tool predicting treatment outcomes based on patient-reportable information
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Machine learning tool with top ten predictors
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Amisulpride and olanzapine
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier log-rank analyses
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Generalised linear mixed-effects models
Number of subjects: 334
Study: 25680824

Group type: EXPERIMENTAL
Intervention: E-learning (17 min duration, using an inflatable manikin)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Instructor-led training (2 hours)
Number of subjects: 160
Study: 23619172

Group type: EXPERIMENTAL
Intervention: Intellivent
Number of subjects: 14

Group type: COMPARATOR
Intervention: PSV
Number of subjects: 14
Study: 20539296

Group type: EXPERIMENTAL
Intervention: WLM
Number of subjects: 48

Group type: COMPARATOR
Intervention: NW
Number of subjects: 48

Group type: COMPARATOR
Intervention: OB
Number of subjects: 48
Study: 18350395

Group type: EXPERIMENTAL
Intervention: Switch with warning (high and low salience signals)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Switch without warning (high and low salience signals)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: No switch (high and low salience signals)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High salience signals
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low salience signals
Number of subjects: 20
Study: 16553052

Group type: EXPERIMENTAL
Intervention: Preoperative biliary-drainage strategy (standard strategy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early-surgery strategy
Number of subjects: 0
Study: 12805393

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 64 mg daily
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 96 mg daily
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 192 mg daily
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 384 mg daily
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 385
Study: 10485241

Group type: EXPERIMENTAL
Intervention: Flow rate of 2.0 ml/s
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Flow rate of 3.0 ml/s
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Flow rates of 2.0 ml/s, 3.0 ml/s, and 4.0 ml/s
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Timing of the third helical examination
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Injection of 120 ml contrast medium with a flow rate of 3.0 ml/s
Number of subjects: 125
Study: 8561334

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (10 mL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Etidocaine 1% (10 mL)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 38
Study: 1759769

Group type: EXPERIMENTAL
Intervention: Postoperative autologous blood salvage and reinfusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no autologous blood salvage)
Number of subjects: 40
Study: 7046900

Group type: EXPERIMENTAL
Intervention: CMFVP
Number of subjects: 312

Group type: COMPARATOR
Intervention: L-PAM
Number of subjects: 312
Study: 31287797

Group type: EXPERIMENTAL
Intervention: Acupressure applied at three acupoints
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sham acupressure (placebo)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Routine care only (control)
Number of subjects: 144
Study: 28592147

Group type: EXPERIMENTAL
Intervention: Intensive and multidisciplinary program conducted in a rehabilitation center
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Less intensive outpatient program conducted by a trained private physiotherapist
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Mixed strategy combining the same outpatient program associated with a weekly multidisciplinary intervention
Number of subjects: 159

Group type: COMPARATOR
Intervention: All treatment strategies
Number of subjects: 159
Study: 26071616

Group type: EXPERIMENTAL
Intervention: aCRT
Number of subjects: 478

Group type: COMPARATOR
Intervention: Echo
Number of subjects: 478
Study: 24760536

Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 22804972

Group type: EXPERIMENTAL
Intervention: Sodium phosphate (50 mg/kg of fat-free mass per day)
Number of subjects: 20
Study: 19225858

Group type: EXPERIMENTAL
Intervention: Mesh-plug tension-free (MPTF) hernia repair
Number of subjects: 106

Group type: COMPARATOR
Intervention: Open-tension (OT) hernia repair
Number of subjects: 106
Study: 17287327

Group type: EXPERIMENTAL
Intervention: Test tampon with apertured film cover
Number of subjects: 105

Group type: COMPARATOR
Intervention: Reference tampon with nonwoven fleece cover
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both test and reference tampons
Number of subjects: 105
Study: 15067698

Group type: EXPERIMENTAL
Intervention: Melt extrusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Film-coated beads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glass thermoplastic system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmanipulated drug
Number of subjects: 0
Study: 11144994

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.5 mg as an intravenous (i.v.) infusion over 15 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.5 mg as an intramuscular (i.m.) injection
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10096255

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Seville orange juice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6',7'-Dihydroxybergamottin
Number of subjects: 0
Study: 7704983

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tissue plasminogen activator (TPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All trials
Number of subjects: 0
Study: 2280242

Group type: EXPERIMENTAL
Intervention: Symptomatic hypoglycaemia
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Biochemical hypoglycaemia
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Symptomatic episodes
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Biochemical episodes
Number of subjects: 66
Study: 6448620

Group type: EXPERIMENTAL
Intervention: Atropine (large doses)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ipratropium bromide (conventional doses)
Number of subjects: 9
Study: 29458401

Group type: EXPERIMENTAL
Intervention: Ding-Kun-Dan (DKD) pre-treatment for 3 months before IVF/ICSI
Number of subjects: 278
Study: 27197829

Group type: EXPERIMENTAL
Intervention: NGT decompression (NGT group; n=108)
Number of subjects: 210

Group type: COMPARATOR
Intervention: No NGT decompression (no-NGT group; n=102)
Number of subjects: 210
Study: 24602082

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser at 0.25 W
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser at 0.5 W
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (same laser applied without laser emission)
Number of subjects: 20
Study: 22738299

Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 15